Evaluation Targeting IL-23 in IBD: Updates in Emerging Therapies and Patient-Centered Care Evaluation HMP Education would appreciate your feedback on the quality and impact of this activity.Please answer the following questions, some of which include a 5-point Likert scale (5 = strongly agree/excellent/great deal; 1 = strongly disagree/poor/very little). To what extent are you able to better achieve each of the following learning objectives? Evaluate current challenges in IBD treatment including the need for novel targeted strategies 5 4 3 2 1 Describe the mechanism of action of IL-23 in IBD pathogenesis and their utility in clinical practice 5 4 3 2 1 Assess the safety and efficacy of current and emerging IL-12/23 and IL-23 inhibitors as well as key considerations and real-world evidence for their optimal use and sequencing in IBD treatment 5 4 3 2 1 Outline strategies to address patient needs and provide individualized care through consistent communication and shared decision-making 5 4 3 2 1 Please rate the faculty on their knowledge, expertise, and teaching ability (5= excellent, 3 = good, 1 = poor). Raymond K. Cross, Jr., MD, MS, AGAF, FACG 5 4 3 2 1 Aline Charabaty, MD 5 4 3 2 1 David P. Hudesman, MD, FACG, AGAF 5 4 3 2 1 Please rate the following components relating to this activity: Content 5 4 3 2 1 Relevance to your practice 5 4 3 2 1 Educational format 5 4 3 2 1 Audience-participation portions (eg., Q&A, polling, pre/post-testing) 5 4 3 2 1 Resources and/or other materials supporting the activity 5 4 3 2 1 Overall 5 4 3 2 1 Therapeutic recommendations presented in this activity did not encourage inappropriate or excessive use of products/devices. Agree Disagree How many patients do you encounter with Crohn's Disease and Ulcerative Colitis on a weekly basis? 0 patients 1-10 patients 11-20 patients 21-30 patients More than 30 patients Do you feel like there were any new data presented? Yes, please specify: No Did you learn anything new? Yes, please specify: No Did you gain confidence on the new information? Yes, why? No, why? Did this program include opportunities to learn as a part of a healthcare team? Yes, please specify: No According to current data, approximately what percentage of patients are primary non-responders? 10% - 20% 10% - 30% 20% - 30% 20% - 40% Which of the following cytokines promotes the induction of a Th17 immune response and the production of inflammatory cytokines involved in IBD pathogenesis? TNF-a IL-17 IL-21 IL-23 Data from the SUCCESS consortium demonstrated that bio-naïve IBD patients treated with _______, saw higher rates of clinical and endoscopic remission. Brazikumab Guselkumab Risankizumab Ustekinumab A comparative safety cohort study demonstrated that ustekinumab treatment was associated with a lower risk of which AE, compared to TNF-a antagonists? Anemia Rashes Risk of serious infection Risk of hospitalization How confident are you now in your ability to utilize shared decision-making strategies to individualize patient care? Very confident Confident Somewhat confident Not very confident Not at all confident Do you intend to make any additional changes to your practice as a result of information gained from this activity? Please be specific. Yes, please describe: No What challenges or barriers outside of your control may prevent you from changing your practice? Adverse effects of available treatments Affordability/cost Institutional policy Insurance/formulary Lack of patient education/engagement Limited resources/time Need more information on optimal management strategies Outdated or unclear guidelines Patient adherence Other: How might future activities help you address those barriers? 255 characters max The information presented in this activity did not serve to advance a proprietary interest of any commercial entity. Agree Disagree Based on my participation in this activity, I anticipate I will more often (select all that apply): Engage in shared decision-making strategies with my patients to promote optimal outcomes Implement IL-23 inhibitor treatment in clinical practice where appropriate Evaluate real-world data regarding current IL inhibitors in IBD Consider clinical trial data and real-world results when determining therapeutic positioning Remain apprised of guideline recommendations and updates for IBD care Use patient preferences and goals to guide IBD treatment decisions Other (please specify): Previous